Results of preclinical studies have shown that inhibition of RANK/RANKL signaling decreases tumor growth and/or establishment and prevented osteolysis in CaP [16,18-22] and other tumor types [23-25] in the bone environment. The gene discussed is TNFRSF11A; the disease is neoplasm.